Kendra Sweet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kendra Sweet has a total of 288 co-authors. Here are the top co-authors by number of shared publications:
- Rami Komrokji
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
51 shared publications - David A. Sallman
Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
49 shared publications - Jeffrey Lancet
H. Lee Moffitt Cancer Center and Research Institute
47 shared publications - Andrew Kuykendall
Moffitt Cancer Center, Tampa, USA
43 shared publications - Eric Padron
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
41 shared publications - Onyee Chan
Department of Malignant Hematology, Moffitt Cancer Center, Tampa, USA
39 shared publications
Latest Publications
- 12 August 2026
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (10) , 1179-1194
Nilotinib in chronic myeloid leukemia: clinical value, real-world challenges, and the potential of nilotinib tablets to improve therapeutic outcomes
1. Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell malignancy distinguished by the Philadelphia (Ph) chromosome, which results from an unbalanced reciprocal translocation of chro...
- 12 August 2026
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (10) , 1179-1194
Nilotinib in chronic myeloid leukemia: clinical value, real-world challenges, and the potential of nilotinib tablets to improve therapeutic outcomes
1. Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell malignancy distinguished by the Philadelphia (Ph) chromosome, which results from an unbalanced reciprocal translocation of chro...
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Table 7. Targeted Next Generation Sequencing (NGS) panels used for the Moffitt Cancer Center, Nice University Hospital, and University of Maryland Cohorts.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Table 7. Targeted Next Generation Sequencing (NGS) panels used for the Moffitt Cancer Center, Nice University Hospital, and University of Maryland Cohorts.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Table 2. Predictors of complete response with (CR) or without (CRi) count recovery.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Table 2. Predictors of complete response with (CR) or without (CRi) count recovery.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 10. Nested Bootstrap Analysis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 10. Nested Bootstrap Analysis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 1. Study Flow and Model Development Pipeline.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 1. Study Flow and Model Development Pipeline.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 12 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 12. Comparison of Risk Group Classifications Between the Moffitt Model vs. Other Prognostic Models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 12 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 12. Comparison of Risk Group Classifications Between the Moffitt Model vs. Other Prognostic Models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Table 3. Predictors of Overall Survival.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Table 3. Predictors of Overall Survival.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 6. OS outcomes based on clinical factors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 6. OS outcomes based on clinical factors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 15 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 15. Effect of Genetic Risk, AML Subtype, Prior HMA Exposure, and Allo-SCT on OS.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 15 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 15. Effect of Genetic Risk, AML Subtype, Prior HMA Exposure, and Allo-SCT on OS.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 8. Impact of TP53 Mutation and Complex Karyotype on Multivariable Coefficients and Collinearity.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 8. Impact of TP53 Mutation and Complex Karyotype on Multivariable Coefficients and Collinearity.